MPP4

Summary

MPP4 (MAGUK p55 scaffold protein 4, HGNC:13680) is a protein-coding gene on chromosome 2q33.1, encoding MAGUK p55 subfamily member 4 (Q96JB8). May play a role in retinal photoreceptors development.

This gene encodes a member of the membrane-associated guanylate kinase (MAGUK) protein family, with an N-terminal PDZ domain, a central src homology 3 region (SH3), and a C-terminal guanylate kinase-like (GUK) domain. The protein is localized to the outer limiting membrane in the retina, and is thought to function in photoreceptor polarity and the organization of specialized intercellular junctions. Alternatively spliced transcript variants have been described, but their biological validity has not been determined.

Source: NCBI Gene 58538 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 113 total — 2 pathogenic
• MANE Select transcript: NM_033066

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13680
Approved symbol	MPP4
Name	MAGUK p55 scaffold protein 4
Location	2q33.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000082126
Ensembl biotype	protein_coding
OMIM	606575
Entrez	58538

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 11 protein_coding, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000315506, ENST00000359962, ENST00000396886, ENST00000409143, ENST00000409474, ENST00000409818, ENST00000428900, ENST00000447335, ENST00000483841, ENST00000486212, ENST00000602867, ENST00000620095, ENST00000959424, ENST00000959425

RefSeq mRNA: 1 — MANE Select: NM_033066 NM_033066

CCDS: CCDS46491

Canonical transcript exons

ENST00000409474 — 22 exons

Exon	Start	End
ENSE00001172760	201675207	201675271
ENSE00001330653	201685919	201686050
ENSE00001424090	201666334	201666372
ENSE00001623453	201650072	201650165
ENSE00003266762	201649576	201649684
ENSE00003304876	201647691	201647825
ENSE00003467422	201685064	201685145
ENSE00003478496	201658477	201658518
ENSE00003510791	201680838	201681034
ENSE00003512162	201687291	201687371
ENSE00003551864	201682831	201682916
ENSE00003581681	201690202	201690279
ENSE00003599982	201664081	201664101
ENSE00003600468	201656198	201656368
ENSE00003627926	201692908	201693029
ENSE00003646870	201669733	201669750
ENSE00003662607	201654837	201654917
ENSE00003665545	201681496	201681567
ENSE00003668186	201693876	201694054
ENSE00003680425	201660332	201660346
ENSE00003842604	201698587	201698644
ENSE00003844181	201644874	201645404

Expression profiles

Bgee: expression breadth ubiquitous, 122 present calls, max score 80.31.

FANTOM5 (CAGE): breadth broad, TPM avg 1.4867 / max 156.0572, expressed in 435 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
33255	0.4622	179
33252	0.3591	204
33256	0.2268	112
33248	0.1460	60
33249	0.0815	29
33250	0.0678	21
33257	0.0491	14
33251	0.0422	14
33253	0.0236	6
33258	0.0208	6

Top tissues by expression

223 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	80.31	gold quality
oocyte	CL:0000023	77.00	silver quality
cerebellar hemisphere	UBERON:0002245	65.84	gold quality
cerebellar cortex	UBERON:0002129	65.78	gold quality
right hemisphere of cerebellum	UBERON:0014890	64.75	gold quality
cerebellum	UBERON:0002037	64.46	gold quality
stromal cell of endometrium	CL:0002255	62.27	gold quality
sural nerve	UBERON:0015488	59.68	gold quality
spleen	UBERON:0002106	57.59	gold quality
vena cava	UBERON:0004087	57.47	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	55.44	gold quality
ectocervix	UBERON:0012249	55.02	gold quality
nasal cavity epithelium	UBERON:0005384	54.47	gold quality
left adrenal gland	UBERON:0001234	54.08	gold quality
parotid gland	UBERON:0001831	53.82	gold quality
left adrenal gland cortex	UBERON:0035825	53.71	gold quality
islet of Langerhans	UBERON:0000006	52.72	gold quality
right adrenal gland	UBERON:0001233	52.50	gold quality
adrenal cortex	UBERON:0001235	52.49	gold quality
retina	UBERON:0000966	52.47	gold quality
pigmented layer of retina	UBERON:0001782	52.46	silver quality
right adrenal gland cortex	UBERON:0035827	52.36	gold quality
Brodmann (1909) area 9	UBERON:0013540	51.63	gold quality
adrenal gland	UBERON:0002369	51.45	gold quality
hindlimb stylopod muscle	UBERON:0004252	50.65	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	50.52	gold quality
vagina	UBERON:0000996	49.87	gold quality
right frontal lobe	UBERON:0002810	49.28	gold quality
right lung	UBERON:0002167	49.04	gold quality
endocervix	UBERON:0000458	48.82	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-137537	yes	1779.42
E-MTAB-7316	yes	34.34
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

22 targeting MPP4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-766-3P	99.47	65.24	1811
HSA-MIR-302A-5P	99.39	68.21	1913
HSA-MIR-5190	99.15	67.76	1234
HSA-MIR-3164	99.02	68.39	1071
HSA-MIR-6820-3P	99.02	68.50	1035
HSA-MIR-3613-5P	98.40	68.91	604
HSA-MIR-338-3P	98.14	67.38	1137
HSA-MIR-6841-5P	97.19	67.29	409
HSA-MIR-382-5P	96.71	65.90	762
HSA-MIR-597-3P	96.46	68.03	1035
HSA-MIR-4793-3P	94.87	65.85	896

Literature-anchored findings (GeneRIF, showing 2)

• MPP4 gene is highly expressed in retina, but no mutations were identified in a panel of 300 unrelated patients with retinitis pigmentosa. (PMID:12384283)
• Bipolar disorder participants with a history of Suicidal behavior showed less overall methylation in the 5’ untranslated region of Membrane palmitoylated protein 4 . (PMID:28276657)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	mpp4l	ENSDARG00000009386
danio_rerio	mpp4a	ENSDARG00000058222
danio_rerio	mpp4b	ENSDARG00000076872
mus_musculus	Mpp4	ENSMUSG00000079550
rattus_norvegicus	Mpp4	ENSRNOG00000010486
drosophila_melanogaster	metro	FBGN0050021
drosophila_melanogaster	vari	FBGN0250785
caenorhabditis_elegans	magu-3	WBGENE00016841
caenorhabditis_elegans		WBGENE00021914

Paralogs (7): PALS1 (ENSG00000072415), PALS2 (ENSG00000105926), MPP2 (ENSG00000108852), MPP1 (ENSG00000130830), CASK (ENSG00000147044), MPP7 (ENSG00000150054), MPP3 (ENSG00000161647)

Protein

Protein identifiers

MAGUK p55 subfamily member 4 — Q96JB8 (reviewed: Q96JB8)

Alternative names: Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 5 protein, Discs large homolog 6

All UniProt accessions (8): Q96JB8, A0A087WUS1, E7ET46, E7EUL8, E9PG92, F6Q0Y6, F8WBH8, R4GN59

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in retinal photoreceptors development.

Subunit / interactions. Interacts with MPDZ. May interact with GRIA2. Forms a complex with CRB1 and PALS1. Interacts with FASLG.

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in the retina (at protein level). Highly expressed in the retina. Lower amounts are detected in brain, testis, ARPE-19, RPE/choroid and fetal eye. Isoform 5 is retina-specific.

Similarity. Belongs to the MAGUK family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q96JB8-1	1	yes
Q96JB8-2	2
Q96JB8-3	3
Q96JB8-4	4
Q96JB8-5	5

RefSeq proteins (1): NP_149055* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001452	SH3_domain	Domain
IPR001478	PDZ	Domain
IPR004172	L27_dom	Domain
IPR008144	Guanylate_kin-like_dom	Domain
IPR008145	GK/Ca_channel_bsu	Domain
IPR014775	L27_C	Domain
IPR020590	Guanylate_kinase_CS	Conserved_site
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR035600	MPP4_SH3	Domain
IPR036028	SH3-like_dom_sf	Homologous_superfamily
IPR036034	PDZ_sf	Homologous_superfamily
IPR036892	L27_dom_sf	Homologous_superfamily
IPR050716	MAGUK	Family

Pfam: PF00595, PF00625, PF02828

UniProt features (19 total): splice variant 7, domain 5, sequence variant 2, chain 1, sequence conflict 1, region of interest 1, coiled-coil region 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96JB8-F1	76.39	0.42

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 60 (showing top): HORIUCHI_WTAP_TARGETS_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, OCT1_03, SENESE_HDAC1_TARGETS_UP, GOBP_PROTEIN_LOCALIZATION_TO_SYNAPSE, HAN_SATB1_TARGETS_DN, GOCC_CELL_CELL_JUNCTION, MODULE_95, TUOMISTO_TUMOR_SUPPRESSION_BY_COL13A1_DN, GOCC_ANCHORING_JUNCTION, MATSUDA_NATURAL_KILLER_DIFFERENTIATION, BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_UP, GOBP_PROTEIN_LOCALIZATION_TO_CELL_JUNCTION, MODULE_163

GO Biological Process (2): protein localization to synapse (GO:0035418), intracellular protein localization (GO:0008104)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (8): cytosol (GO:0005829), plasma membrane (GO:0005886), adherens junction (GO:0005912), actin cytoskeleton (GO:0015629), protein-containing complex (GO:0032991), cytoplasm (GO:0005737), membrane (GO:0016020), anchoring junction (GO:0070161)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
protein localization to cell junction	1
macromolecule localization	1
binding	1
cytoplasm	1
membrane	1
cell periphery	1
cell-cell junction	1
cytoskeleton	1
cellular_component	1
intracellular anatomical structure	1
cell junction	1

Protein interactions and networks

STRING

1100 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MPP4	GRK7	Q8WTQ7	762
MPP4	ITPR2	Q14571	750
MPP4	GRK1	Q15835	741
MPP4	RCVRN	P35243	714
MPP4	ATP2A2	P16614	592
MPP4	RHO	P08100	507
MPP4	PDZD9	Q8IXQ8	507
MPP4	CDK2AP1	O14519	430
MPP4	CRB2	Q5IJ48	416
MPP4	XKR3	Q5GH77	400
MPP4	ZC3H11B	A0A1B0GTU1	398
MPP4	ORMDL2	Q53FV1	384
MPP4	CMSS1	Q9BQ75	351
MPP4	GART	P22102	348
MPP4	CCPG1	Q9ULG6	336

IntAct

35 interactions, top by confidence:

A	B	Type	Score
PALS1	MPP4	psi-mi:“MI:0915”(physical association)	0.630
MPP4	CRB1	psi-mi:“MI:0915”(physical association)	0.520
MPP4	FASLG	psi-mi:“MI:0407”(direct interaction)	0.440
CREBBP	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
ABCC4	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
ARHGEF16	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
ASIC3	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
ATP2B4	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
CYSLTR2	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
DGKK	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
DGKZ	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
DOCK4	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
FRMPD4	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
FZD7	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
TAMALIN	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
E6	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
ORF putative E6	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
KCNA5	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
KIR3DL3	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
MAP2K2	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
PBK	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
RALBP1	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440
RASSF6	MPP4	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (4): PLEKHF2 (Two-hybrid), MPP4 (Affinity Capture-MS), MPP4 (Reconstituted Complex), MPP4 (Protein-peptide)

ESM2 similar proteins: A0AVI2, A0FGR9, A0JP70, A2AAJ9, A2ABU4, A2RUH7, A6QQP7, O01761, O14976, O15068, O70145, O70468, O75923, O77775, O88599, P0C5E3, P11799, P19878, P56741, P70402, P70600, P97874, Q05623, Q13203, Q14289, Q15746, Q29RQ5, Q3UMY5, Q5DTI8, Q5FW53, Q5PQM4, Q5RKG2, Q5VST9, Q5VTT5, Q62234, Q64096, Q6P7F1, Q7ZZC8, Q80W93, Q8C7M3

Diamond homologs: A6QQZ7, A8KBF6, A9CB74, B4F7E7, D3ZAA9, E2QY99, G5ECY0, O14936, O34328, O70589, O88910, O88954, P0C0M9, P15454, P31006, P31007, P44310, P46195, P49697, P54936, P65219, P65220, P65221, P70175, P70290, P72648, P93757, P99176, Q00013, Q13368, Q14168, Q15700, Q16774, Q17QN6, Q182S8, Q24210, Q2FHM9, Q2G1U0, Q2QPW1, Q2S8R2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

113 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	95
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
2423585	NC_000002.11:g.(?202501451)(202633608_?)del	Pathogenic
375383	NM_033066.3(MPP4):c.946T>C (p.Trp316Arg)	Pathogenic

SpliceAI

2976 predictions. Top by Δscore:

Variant	Effect	Δscore
2:201645404:CCTT:C	acceptor_gain	1.0000
2:201645407:T:C	acceptor_gain	1.0000
2:201645416:A:AC	acceptor_gain	1.0000
2:201647687:TTACC:T	donor_loss	1.0000
2:201647688:TACCT:T	donor_loss	1.0000
2:201647689:A:AC	donor_gain	1.0000
2:201647689:A:T	donor_loss	1.0000
2:201647690:C:CC	donor_gain	1.0000
2:201647690:CCTTG:C	donor_loss	1.0000
2:201647822:TATC:T	acceptor_gain	1.0000
2:201647824:TC:T	acceptor_gain	1.0000
2:201647824:TCC:T	acceptor_loss	1.0000
2:201647825:CC:C	acceptor_gain	1.0000
2:201647826:C:CC	acceptor_gain	1.0000
2:201654835:A:AC	donor_gain	1.0000
2:201654836:C:CC	donor_gain	1.0000
2:201680837:CCT:C	donor_gain	1.0000
2:201681492:TTACC:T	donor_loss	1.0000
2:201681493:TACCA:T	donor_loss	1.0000
2:201681494:A:AT	donor_loss	1.0000
2:201681495:C:CT	donor_loss	1.0000
2:201681495:CCAT:C	donor_gain	1.0000
2:201681564:TGGC:T	acceptor_gain	1.0000
2:201682826:TTTA:T	donor_loss	1.0000
2:201682827:TTA:T	donor_loss	1.0000
2:201682828:TACCA:T	donor_loss	1.0000
2:201682829:ACCA:A	donor_loss	1.0000
2:201682912:CAACC:C	acceptor_gain	1.0000
2:201682915:CC:C	acceptor_gain	1.0000
2:201682916:CC:C	acceptor_gain	1.0000

AlphaMissense

4227 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:201685135:A:T	I168N	0.995
2:201649646:C:T	G505D	0.993
2:201680911:A:G	W286R	0.993
2:201680911:A:T	W286R	0.993
2:201681542:A:G	F229S	0.993
2:201650121:A:G	Y476H	0.992
2:201654890:A:G	L443P	0.991
2:201650156:C:G	R464P	0.990
2:201680940:A:G	L276P	0.990
2:201685135:A:C	I168S	0.989
2:201685141:G:T	A166D	0.989
2:201645254:A:G	W624R	0.988
2:201645254:A:T	W624R	0.988
2:201650157:G:T	R464S	0.988
2:201654878:A:G	L447P	0.988
2:201647782:A:T	I543K	0.987
2:201649595:A:T	V522D	0.987
2:201680862:A:T	V302D	0.987
2:201680909:C:A	W286C	0.987
2:201680909:C:G	W286C	0.987
2:201685096:C:A	R181M	0.987
2:201685142:C:G	A166P	0.987
2:201656198:C:G	G434R	0.986
2:201656198:C:T	G434R	0.986
2:201654886:T:A	R444S	0.985
2:201654886:T:G	R444S	0.985
2:201680901:G:T	A289D	0.985
2:201680908:A:G	W287R	0.985
2:201680908:A:T	W287R	0.985
2:201680957:G:C	F270L	0.985

dbSNP variants (sampled 300 via entrez): RS1000025660 (2:201654123 G>A), RS1000062319 (2:201660615 G>A), RS1000137274 (2:201673919 T>C), RS1000213495 (2:201675101 C>T), RS1000225998 (2:201678095 T>C), RS1000246032 (2:201683960 C>T), RS1000305673 (2:201686434 C>T), RS1000437095 (2:201690400 T>G), RS1000490182 (2:201647919 A>G), RS1000491431 (2:201668054 C>T), RS1000505633 (2:201698401 TCTCGAAGCA>T), RS1000522402 (2:201669350 C>T), RS1000545668 (2:201665279 G>C), RS1000587322 (2:201676051 T>C), RS1000647501 (2:201674836 T>C)

Disease associations

OMIM: gene MIM:606575 | disease phenotypes: MIM:607225, MIM:614424

GenCC curated gene-disease

Mondo (4): infantile-onset ascending hereditary spastic paralysis (MONDO:0011797), Joubert syndrome 14 (MONDO:0013745), intellectual disability (MONDO:0001071), strabismus (MONDO:0003432)

Orphanet (2): Infantile-onset ascending hereditary spastic paralysis (Orphanet:293168), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D013285	Strabismus	C10.292.562.887; C11.590.810
C537217	Hereditary spastic paralysis, infantile onset ascending (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	decreases expression	2
aristolochic acid I	increases expression	1
propionaldehyde	increases expression	1
cobaltous chloride	decreases expression	1
potassium chromate(VI)	decreases expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
Temozolomide	decreases expression	1
Arsenic Trioxide	increases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Formaldehyde	decreases expression	1
Oxygen	increases expression	1
Silicon Dioxide	increases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	increases expression	1
Vanadates	increases expression	1
Aflatoxin B1	increases methylation	1

Clinical trials (associated diseases)

299 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT00461656	PHASE4	COMPLETED	Povidone-iodine Antisepsis for Strabismus Surgery
NCT01901588	PHASE4	COMPLETED	Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery
NCT02379546	PHASE4	COMPLETED	The Effect of Anaesthesia Depth on Oculo-cardiac Reflex
NCT03349515	PHASE4	COMPLETED	The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia.
NCT04549844	PHASE4	UNKNOWN	Peribulbar Block for Prevention of Oculocardiac Reflex
NCT06035757	PHASE4	RECRUITING	The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery
NCT06560268	PHASE4	NOT_YET_RECRUITING	Low Flow Anesthesia in Children Undergoing Strabismus Surgery
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT00000128	PHASE3	UNKNOWN	A Trial of Bifocals in Myopic Children With Esophoria
NCT00001864	PHASE3	COMPLETED	Amblyopia (Lazy Eye) Treatment Study
NCT00038753	PHASE3	UNKNOWN	Vision In Preschoolers Study (VIP Study)
NCT01584843	PHASE3	COMPLETED	Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus
NCT04060771	PHASE3	UNKNOWN	Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery
NCT06863675	PHASE3	NOT_YET_RECRUITING	Highly Aspherical Lenslet (HAL) and Binocular Vision (BV) Disorders [HALT X(T) Study]
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT00478907	PHASE2	COMPLETED	Prevention of Complications of Eye Surgery
NCT06689943	PHASE2	NOT_YET_RECRUITING	Pain After Strabismus Surgery
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT00917982	PHASE1	UNKNOWN	The Effect of Vision Therapy/Orthoptic on Motor & Sensory Status of the 3 to 7 Years Old Strabismic Patients
NCT02246556	PHASE1	TERMINATED	Dichoptic Virtual Reality Therapy for Amblyopia in Adults
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities